Combination therapy aims to boost response in rare skin cancers

NCT ID NCT04256018

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial tests whether combining the drug mogamulizumab with low-dose total skin electron beam therapy works better than either alone for people with mycosis fungoides or Sezary syndrome, two rare types of skin lymphoma. Participants receive both treatments over several weeks. The study measures how many people's cancer shrinks or disappears, and how long that effect lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mogamulizumab and low-dose total skin electron beam therapy
What this could lead to: If successful, this combination could offer a more effective treatment option for people with advanced stages of mycosis fungoides and Sezary syndrome, potentially leading to better disease control.
What could go wrong: This is a small, early-phase study (30 participants) at a single center, so results may not apply broadly. The combination may cause side effects from both the drug and radiation, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOSIS FUNGOIDES SEZARY SYNDROME

Contacts and locations

Locations

Stanford Cancer Center
RECRUITING

Stanford, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.